Tirzepatide in Con Dao: What Cardiometabolic Risk Markers Can Tell Us Beyond Body Weight

Featured Answer

What can cardiometabolic risk markers tell us about tirzepatide beyond body weight?

They can show whether several dimensions of metabolic health are changing alongside weight. Clinical trials have reported improvements in glycemic control, waist circumference, blood pressure, and selected lipid measures with tirzepatide. A 2026 post hoc analysis of SURMOUNT-1 also found favorable changes in multiple biomarkers related to inflammation, insulin resistance, adiposity, hepatic stress, endothelial dysfunction, and hemostasis.

These findings add biological context to weight loss, but they must be interpreted carefully. Biomarkers are not interchangeable with clinical outcomes such as myocardial infarction, stroke, heart failure, or cardiovascular death. Many biomarker changes were associated with changes in weight and waist circumference, so the analysis does not establish that the effects were independent of weight loss.

Clinical-outcome evidence adds another layer. In SURPASS-CVOT, tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, but it was not shown to be statistically superior to dulaglutide for the primary outcome. The most accurate interpretation is therefore that tirzepatide affects multiple cardiometabolic pathways, while the significance of each marker depends on its validation, the patient population, and the clinical endpoint being considered.

1. Introduction: Why Body Weight Is Only One Part of the Picture

Con Dao is often associated with outdoor activity, coastal landscapes, and a lifestyle that may involve walking, swimming, or other forms of exercise. But physical activity and appearance do not, by themselves, reveal a person’s underlying cardiometabolic health. Blood glucose regulation, blood pressure, lipid metabolism, inflammation, liver function, and kidney health can vary substantially between people with similar body weights.

This distinction is important when interpreting tirzepatide research. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It has demonstrated substantial effects on glycemic control and body weight in clinical trials. Researchers have also investigated changes in additional measurements that may help explain how treatment affects metabolic health.

The phrase “beyond body weight” can mean two different things. First, it can refer to outcomes other than weight that matter clinically, such as HbA1c, blood pressure, and lipid levels. Second, it can mean biological effects that occur independently of weight reduction. These are not the same claim.

A treatment may improve a biomarker while a person is losing weight, but that observation alone cannot establish whether the change results from the medication’s direct pharmacological effects, reduced adiposity, changes in food intake, improved glycemia, or several interacting processes.

The most useful approach is to distinguish established clinical risk factors, exploratory biomarkers, and hard clinical outcomes. Each provides different information and carries a different level of certainty.

2. What Is Tirzepatide and How Does It Work?

Tirzepatide is a synthetic peptide-based medicine that activates both GIP and GLP-1 receptors. These receptors participate in nutrient-responsive signaling and glucose homeostasis. Their activation influences glucose-dependent insulin secretion and other physiological processes involved in appetite regulation and energy balance.

GLP-1 receptor activation contributes to glucose-dependent insulin secretion, suppresses glucagon secretion when appropriate, and influences appetite and gastrointestinal physiology. GIP receptor activation also participates in nutrient-responsive insulin secretion. The combined pharmacology of tirzepatide produces substantial effects on glycemic control and body weight in the populations studied.

Its clinical effects are not limited to the number displayed on a scale. Trials have also assessed waist circumference, blood pressure, lipid measurements, insulin-related markers, and other metabolic variables. These outcomes can help characterize the broader response to treatment.

However, the existence of multiple biological effects should not be interpreted as proof that every pathway has an independent or clinically meaningful contribution to cardiovascular risk reduction. Establishing that relationship requires more than observing changes in laboratory values.

For approved uses, prescribing decisions should follow the current product information and a clinician’s assessment of the person’s diagnosis, other medications, contraindications, and treatment goals. Research on possible cardiometabolic effects does not justify using tirzepatide outside appropriate medical supervision.

3. Cardiometabolic Risk: A Network Rather Than a Single Number

Cardiometabolic risk refers to interacting factors that influence the likelihood of conditions such as type 2 diabetes, atherosclerotic cardiovascular disease, and other metabolic complications. It is not represented adequately by body weight alone.

Several established measurements help describe this network:

• Glycemic markers: HbA1c and blood glucose measurements characterize glucose regulation.
• Blood pressure: Systolic and diastolic pressure reflect an important, modifiable cardiovascular risk factor.
• Lipid measurements: LDL cholesterol, non-HDL cholesterol, triglycerides, and HDL cholesterol provide information about different aspects of lipid metabolism and cardiovascular risk.
• Central adiposity: Waist circumference helps characterize abdominal fat distribution, which may provide information not captured by total body weight.
• Kidney-related measurements: Estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) can help identify kidney disease and contribute to risk assessment.
• Selected biomarkers: Measurements such as hs-CRP or insulin-resistance indices may provide additional biological context in appropriate settings.

These measurements do not have equal roles. HbA1c, blood pressure, and LDL cholesterol are established clinical risk factors with well-developed management frameworks. By contrast, some exploratory biomarkers are more useful for understanding disease mechanisms or studying treatment response than for directing routine care.

A broader biomarker panel may reveal that several pathways are changing at the same time. It does not automatically produce a more accurate individual risk estimate, and it should not replace validated risk-assessment tools or clinically indicated testing.

4. Weight Loss and Waist Circumference: Two Different Measurements

Body weight provides a practical measure of total mass, but it cannot distinguish fat mass from lean mass or show where body fat is distributed. Waist circumference provides complementary information about central adiposity, although it is also an imperfect measurement and depends on standardized technique.

In SURMOUNT-1, adults with obesity or overweight and at least one weight-related complication, but without diabetes, were randomly assigned to tirzepatide or placebo for 72 weeks. The trial reported substantial weight reduction with tirzepatide and improvements in several cardiometabolic risk factors, including waist circumference and blood pressure [1].

These results are relevant because central adiposity is associated with metabolic dysfunction, but waist circumference should not be treated as a direct measurement of visceral fat or as a stand-alone diagnosis. Imaging methods can measure particular fat compartments more directly, although they are not necessary for every routine clinical assessment.

Weight and waist circumference also cannot determine whether an individual has achieved a reduction in cardiovascular events. They are indicators of treatment response and risk context, not complete substitutes for clinical outcomes.

When comparing treatment results, it is useful to examine both absolute and percentage changes, the time point of measurement, the baseline characteristics of the participants, and whether the analysis followed all randomized participants or a selected subgroup.

5. HbA1c and Glucose Regulation: Beyond the Scale

HbA1c estimates average glycemia over approximately the preceding two to three months, with greater influence from more recent glucose levels. It is widely used in the diagnosis and monitoring of diabetes, although conditions affecting red blood cell turnover can complicate interpretation.

Tirzepatide has demonstrated substantial HbA1c reduction in trials involving people with type 2 diabetes. This is clinically important because glycemic control is a central component of diabetes management and can influence the risk of microvascular complications.

However, HbA1c does not measure every aspect of glucose regulation. It does not show day-to-day glucose variability or identify every episode of hypoglycemia. A person with a lower HbA1c may still require assessment of other risk factors and treatment-related adverse effects.

For people with overweight or obesity who do not have diabetes, the interpretation is different. A normal HbA1c does not mean that all cardiometabolic risks are absent, while a change in HbA1c within the normal range does not automatically represent a clinically meaningful benefit.

In the SURMOUNT-1 population with obesity and prediabetes, a subsequent three-year analysis found substantially lower progression to type 2 diabetes during tirzepatide treatment than with placebo. At 176 weeks, diabetes was diagnosed in 1.3% of participants assigned to tirzepatide compared with 13.3% assigned to placebo; the study also reported weight reduction over the same period [4]. These results apply to the studied population and should not be generalized to every person or interpreted as proof that treatment permanently prevents diabetes after discontinuation.

6. Blood Pressure: A Risk Factor That May Change Alongside Weight

Blood pressure is an established cardiovascular risk factor. Persistently elevated pressure contributes to vascular stress and increases the risk of cardiovascular and kidney complications.

Clinical trials and pooled analyses have reported reductions in blood pressure with tirzepatide. A meta-analysis of randomized trials found lower systolic blood pressure across the studied dose groups, alongside changes in selected lipid measures [5]. The size of an average trial effect does not predict the response of every individual.

Blood pressure can be influenced by several factors, including changes in body weight, sodium intake, physical activity, medications, hydration status, and underlying disease. A reduction observed during tirzepatide treatment does not, by itself, reveal how much each factor contributed.

Blood pressure also requires proper measurement. A single reading may be affected by recent activity, stress, posture, cuff size, or measurement technique. Repeated measurements under appropriate conditions are generally more informative than an isolated value.

It is also important to consider the clinical context. People taking antihypertensive medicines may need monitoring as weight, food intake, fluid balance, or other health measures change. Decisions about changing prescribed medication should be made with a healthcare professional rather than based on a single reading.

7. Lipids: Why LDL, Triglycerides, and HDL Should Not Be Treated as One Marker

A lipid panel contains measurements that reflect different aspects of lipid metabolism. LDL cholesterol is a well-established causal contributor to atherosclerotic cardiovascular disease. Triglycerides are associated with metabolic and cardiovascular risk, while HDL cholesterol has a more complex relationship with risk and should not be interpreted as a direct therapeutic target in isolation.

In tirzepatide trials, changes in triglycerides and other lipid measurements have been reported alongside changes in weight and glycemic control. These findings may be consistent with improved metabolic health, but the effect varies by marker, study population, comparator, and duration.

A 2023 meta-analysis of randomized trials found that tirzepatide reduced systolic blood pressure and total cholesterol and reported changes in other lipid measures [5]. More recent cardiovascular-outcome evidence underscores the importance of not assuming that every marker improves to the same degree.

In SURPASS-CVOT, tirzepatide was compared with dulaglutide, a GLP-1 receptor agonist with established cardiovascular benefit, in people with type 2 diabetes and atherosclerotic cardiovascular disease. Tirzepatide was noninferior to dulaglutide for the primary composite outcome of cardiovascular death, myocardial infarction, or stroke, but superiority was not established [3]. A subsequent correspondence also highlighted that LDL cholesterol was not lowered with tirzepatide relative to dulaglutide despite greater weight loss and better glycemic control in the tirzepatide group [6].

This is a useful reminder: improvement in body weight, HbA1c, or selected lipid measurements should not lead to the assumption that LDL cholesterol has reached an appropriate level. LDL-related risk needs to be assessed and managed according to clinical guidelines and individual risk.

8. hs-CRP and IL-6: What Inflammatory Biomarkers Can Tell Us

High-sensitivity C-reactive protein (hs-CRP) is a blood marker of systemic inflammation. Interleukin-6 (IL-6) is a signaling molecule involved in immune and inflammatory responses and participates in the regulation of CRP production.

Both markers have been studied in relation to cardiometabolic disease. Higher hs-CRP can be associated with increased cardiovascular risk, but it is nonspecific: infections, injuries, inflammatory disorders, and other conditions can affect the result. IL-6 is also influenced by multiple biological processes and is not a stand-alone diagnostic test for cardiovascular disease.

A 2026 post hoc analysis of SURMOUNT-1 examined several biomarkers in a randomly selected subset of participants. At week 72, tirzepatide was associated with greater reductions in hs-CRP and IL-6 than placebo. The placebo-adjusted geometric mean reductions in hs-CRP were 36.9%, 46.9%, and 54.6% for the 5 mg, 10 mg, and 15 mg groups, respectively. The corresponding placebo-adjusted reductions in IL-6 were 25.4%, 27.8%, and 30.2% [2].

These findings suggest changes in inflammatory pathways during treatment. They do not prove that the reduction in hs-CRP or IL-6 directly caused fewer cardiovascular events, nor do they establish that every person receiving tirzepatide will experience the same changes.

The analysis was post hoc and involved a subset of the parent trial rather than a trial designed primarily to demonstrate that biomarker changes predict clinical outcomes. In addition, changes in hs-CRP and IL-6 were associated with changes in weight and waist circumference. The data therefore do not establish that the biomarker changes were independent of weight reduction.

9. Insulin Resistance, HOMA-IR, and Leptin

Insulin resistance occurs when tissues respond less effectively to insulin. The pancreas may initially compensate by producing more insulin, helping maintain glucose levels despite reduced insulin sensitivity.

The homeostatic model assessment of insulin resistance (HOMA-IR) is calculated using fasting glucose and insulin measurements. It is used mainly in research and selected clinical contexts. It is not a direct measurement of insulin sensitivity and can be affected by assay methods, fasting conditions, pancreatic function, and the population being studied.

In the 2026 SURMOUNT-1 biomarker analysis, tirzepatide was associated with placebo-adjusted reductions in HOMA-IR of 26.4%, 35.5%, and 39.1% for the 5 mg, 10 mg, and 15 mg groups, respectively, at week 72 [2]. These results are consistent with improved insulin-resistance-related measurements during treatment.

Leptin, a hormone produced largely by adipose tissue, participates in signaling related to energy stores and appetite. Circulating leptin levels are influenced by fat mass and other factors. In the same analysis, leptin decreased substantially relative to placebo, with larger reductions in the higher-dose groups [2].

Neither HOMA-IR nor leptin should be interpreted as a stand-alone measure of cardiovascular protection. Both provide information about aspects of metabolism and adiposity, but their clinical meaning depends on context. A lower value is not automatically better in every physiological situation, and neither marker replaces established assessments such as HbA1c, blood pressure, lipid measurements, or clinical history.

10. Hepatic Stress Markers: Understanding GGT and Related Measures

Gamma-glutamyl transferase (GGT) is an enzyme measured in blood and often considered alongside other liver-related tests. Elevated GGT may be associated with liver or biliary conditions, alcohol exposure, medication effects, and metabolic dysfunction, but it is nonspecific.

The 2026 SURMOUNT-1 biomarker analysis reported reductions in GGT compared with placebo across tirzepatide groups. It also found changes in fibroblast growth factor-21 (FGF-21), adiponectin, and selected measures related to metabolic and hepatic stress [2]. These observations add to the evidence that treatment is associated with changes beyond body weight alone in the descriptive sense of affecting additional biological measurements.

However, these biomarkers do not establish a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD), steatohepatitis, or fibrosis. Liver enzymes can be normal in some people with significant liver disease, and abnormal values can arise for many reasons.

Interpretation of liver health may require medical history, examination, routine laboratory tests, and—in selected circumstances—imaging or validated fibrosis-risk assessment. An improvement in GGT should not be treated as proof that liver structure has normalized or that advanced fibrosis has resolved.

For this reason, changes in hepatic stress markers are best regarded as supportive information rather than a substitute for disease-specific clinical endpoints.

11. Endothelial Function: A Window Into Vascular Biology

The endothelium is the layer of cells lining blood vessels. It participates in vascular tone, inflammation, coagulation, and communication between the bloodstream and surrounding tissues. Endothelial dysfunction is associated with several cardiometabolic conditions, but it is not captured perfectly by a single blood test.

The 2026 SURMOUNT-1 post hoc analysis assessed soluble intercellular adhesion molecule-1 (sICAM-1) and E-selectin, which are related to endothelial activation and cell adhesion. At week 72, E-selectin was lower relative to placebo across all tirzepatide groups, while sICAM-1 showed significant reductions in the 10 mg and 15 mg groups but not in the 5 mg group [2].

These findings suggest that tirzepatide treatment was associated with changes in selected markers linked to endothelial biology. They do not directly measure the ability of blood vessels to dilate, prove reversal of atherosclerosis, or establish a reduction in heart attacks or strokes.

It is also important to distinguish a biomarker that reflects a biological pathway from a validated surrogate endpoint. To serve as a reliable surrogate, a marker must provide evidence that treatment-induced changes in that marker predict changes in the clinical outcome of interest across relevant settings. Biological plausibility alone is insufficient.

12. Hemostasis and Thrombosis: Why the Results Are More Complex

Hemostasis is the physiological process that stops bleeding, while thrombosis refers to clot formation within blood vessels. These systems involve platelets, coagulation proteins, fibrinolysis, endothelial signaling, and other interacting mechanisms.

The 2026 SURMOUNT-1 biomarker analysis included plasminogen activator inhibitor-1 antigen (PAI-1:Ag), tissue plasminogen activator antigen (tPA:Ag), thrombomodulin, and platelet counts. PAI-1:Ag decreased relative to placebo in the tirzepatide groups, while some other measures did not show consistent changes across doses [2].

These results should not be simplified into a claim that tirzepatide “prevents blood clots.” Biomarker concentrations do not provide a complete picture of clotting function, and a favorable change in one marker does not establish a reduction in venous thromboembolism, stroke, or other thrombotic events.

Different markers can respond differently because they reflect distinct regulatory pathways. The absence of a consistent change in one marker does not automatically negate every other observed effect, but neither should selected favorable results be used to imply a broad antithrombotic effect.

Clinical outcomes and appropriately designed trials remain necessary to determine whether treatment changes the risk of specific thrombotic events.

13. The 2026 SURMOUNT-1 Biomarker Analysis: What It Adds

The 2026 analysis published in the Journal of the American College of Cardiology evaluated 16 biomarkers across four broad categories: inflammation; metabolic, adiposity, and hepatic stress; endothelial dysfunction; and hemostasis or thrombosis [2].

Samples were collected at baseline, week 24, and week 72 from randomly selected participants in the parent SURMOUNT-1 trial. After samples with insufficient volume were excluded, the biomarker analysis included 392 participants across placebo and three tirzepatide groups.

At week 72, the authors reported favorable changes in several measures, including hs-CRP, IL-6, HOMA-IR, leptin, GGT, FGF-21, adiponectin, E-selectin, and PAI-1:Ag. Not every marker changed consistently. Fibrinogen, tPA:Ag, and thrombomodulin did not show consistent associations with tirzepatide treatment, while some other results were dose-dependent or statistically significant only at selected doses [2].

This pattern is scientifically informative because cardiometabolic risk is biologically complex. A treatment can affect multiple pathways without producing a uniform response across all measured biomarkers.

Several limitations are important:

• Post hoc design: The analysis was conducted after the parent trial and was not the primary clinical-outcome objective of SURMOUNT-1.
• Subsample size: The biomarker analysis included 392 participants, not the entire parent-trial population.
• Exploratory interpretation: The results help generate and refine hypotheses but do not establish that each biomarker change translates into clinical benefit.
• Association with weight change: Many biomarker changes correlated with changes in weight and waist circumference.
• Uncertain mediation: The analysis does not establish how much of each biomarker change was directly caused by receptor signaling versus downstream changes associated with weight loss or other physiological changes.

The findings broaden the biological picture of tirzepatide treatment. They do not replace cardiovascular-outcome trials or establish a biomarker-based guarantee of risk reduction for an individual patient.

14. Does “Beyond Weight” Mean “Independent of Weight Loss”?

No. This distinction is central to interpreting the evidence.

When a trial reports that weight, blood pressure, hs-CRP, and insulin-resistance markers all improve during treatment, it establishes that these outcomes changed in the treatment group under the study conditions. It does not automatically show that the changes occurred independently of one another.

Weight reduction can itself influence blood pressure, insulin sensitivity, lipid metabolism, liver-related markers, and inflammatory signaling. Tirzepatide may also influence several physiological processes through its receptor activity. The observed treatment response can therefore reflect overlapping direct and indirect effects.

To determine whether a biomarker effect is independent of weight loss, researchers need appropriate analyses and study designs. Simple correlations are not enough. Even statistical adjustment for weight change can be difficult to interpret because weight loss occurs after randomization and may be part of the treatment’s causal pathway.

A strong mechanistic claim requires a clearly defined causal question, suitable data, and careful analysis. The 2026 SURMOUNT-1 biomarker study found that changes in several biomarkers were associated with weight and waist-circumference changes, supporting the relevance of adiposity-related pathways while leaving the independent contribution of different mechanisms unresolved [2].

The most accurate wording is that tirzepatide is associated with changes in multiple cardiometabolic measurements in addition to body weight. Whether a particular change is independent of weight loss, and whether it mediates a clinical benefit, are separate questions.

15. Biomarkers Versus Hard Cardiovascular Outcomes

Cardiovascular research distinguishes between risk markers, surrogate endpoints, and clinical outcomes.

• Risk markers are measurements associated with disease risk, such as blood pressure or hs-CRP.
• Surrogate endpoints are measurements used as substitutes for a clinical outcome when there is sufficient evidence that treatment-induced changes reliably predict that outcome.
• Hard clinical outcomes include events such as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

A favorable biomarker result can support a biological hypothesis, but it does not necessarily predict the size or direction of a treatment’s effect on clinical events. Some interventions improve a marker without producing the expected clinical benefit, while the effects on different outcomes may diverge.

This distinction matters in tirzepatide research. Reductions in hs-CRP or improvements in HOMA-IR are informative, but neither result alone proves that the medicine prevents cardiovascular events. The conclusion must be based on the total evidence, including appropriately designed outcome trials.

For individual care, the established risk factors still matter. A person with improved weight and glycemic control may still have elevated LDL cholesterol, hypertension, kidney disease, or other important risks that require independent assessment.

16. SURPASS-CVOT: What the Cardiovascular Outcomes Trial Shows

SURPASS-CVOT compared tirzepatide with dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Dulaglutide was an active comparator with established cardiovascular benefit, making the trial particularly relevant to comparative cardiovascular safety and outcomes.

The modified intention-to-treat population included 6,586 participants assigned to tirzepatide and 6,579 assigned to dulaglutide. The primary composite outcome of cardiovascular death, myocardial infarction, or stroke occurred in 801 participants (12.2%) in the tirzepatide group and 862 participants (13.1%) in the dulaglutide group. The hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01. The trial met its prespecified noninferiority criterion, but superiority was not established (P=0.09 for superiority) [3].

These findings are important, but their interpretation needs precision.

Noninferiority means the results met the trial’s prespecified criterion for showing that tirzepatide was not unacceptably worse than the active comparator on the primary outcome. It does not mean that tirzepatide was proven superior, nor does it imply that all cardiovascular effects are identical.

The study population also matters. These results apply directly to the studied population with type 2 diabetes and established atherosclerotic cardiovascular disease. They should not automatically be generalized to people without diabetes, people without established cardiovascular disease, or every other clinical context.

In combination with the biomarker data, SURPASS-CVOT supports a more complete interpretation: tirzepatide affects several cardiometabolic measurements and has been compared with an established cardiovascular-benefit medicine in a major outcome trial. The biomarker changes themselves, however, should not be substituted for the clinical-outcome evidence.

17. How Should Clinicians and Researchers Interpret a Biomarker Panel?

A useful interpretation begins with the clinical question. Is the goal to assess diabetes control, estimate cardiovascular risk, investigate a possible liver disorder, monitor kidney health, or understand the biological response to treatment? Different questions require different measurements.

For routine cardiometabolic assessment, established measurements often provide the most actionable information. Depending on the person’s circumstances, these may include HbA1c or blood glucose, blood pressure, a lipid panel, kidney function, urine albumin, and waist circumference. Additional tests should be selected according to the clinical context rather than ordered simply because a treatment study measured them.

Exploratory markers such as IL-6, FGF-21, E-selectin, or PAI-1:Ag can be valuable in research, but they are not all standard tools for routine monitoring of tirzepatide. Their role in individual decision-making depends on validation, availability, and the clinical question.

Researchers should also distinguish between group averages and individual response. A statistically significant average change in a randomized trial does not mean every participant experiences the same direction or magnitude of change.

Finally, a biomarker panel should be interpreted over time. Baseline values, measurement variability, intercurrent illness, medication changes, and the timing of blood collection can all influence results. A single favorable measurement is rarely enough to characterize long-term cardiometabolic risk.

18. Safety Considerations When Interpreting Tirzepatide Outcomes

Potential benefits should be considered alongside safety and tolerability. Gastrointestinal adverse effects, including nausea, vomiting, diarrhea, constipation, and abdominal discomfort, are among the commonly reported effects of tirzepatide. These effects can influence food intake and hydration and may affect how a person tolerates treatment.

Current US prescribing information includes warnings and precautions concerning pancreatitis, gallbladder disease, hypoglycemia when used with insulin or insulin secretagogues, acute kidney injury associated with volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, and diabetic retinopathy complications in relevant populations [7]. The specific prescribing information applicable to a person depends on the product, jurisdiction, indication, and current regulatory label.

Changes in body weight, blood pressure, glucose, and other markers should therefore be interpreted alongside adverse effects, concomitant medication, and clinical status. A favorable change in one risk marker does not eliminate other treatment risks or establish that treatment is appropriate for every person.

Patients should not stop, start, or adjust prescribed medicines based on an isolated biomarker result or an article discussing trial averages. Treatment decisions require individualized clinical assessment.

19. Evidence Summary: What Each Measurement Can and Cannot Tell Us

20. Statistics: Key Findings From Tirzepatide Research

Statistical caution: Percent changes in biomarkers, weight-loss percentages, and cardiovascular-event rates describe different outcomes. They cannot be directly compared or converted into a single estimate of “overall cardiometabolic improvement.” The magnitude of a biomarker change does not determine the magnitude of a change in clinical-event risk.

21. Frequently Asked Questions

22. Related Articles

• Vietnam Peptides Knowledge Hub — Explore educational articles about peptide biology, clinical research, and evidence interpretation.
• Peptide Research FAQ — Review general questions about research peptides and the limitations of scientific claims.
• Peptide Products and Research Categories — Browse research-oriented peptide categories and related product information.
• Tirzepatide 20mg Product Information — Product information page; listing does not establish regulatory approval, suitability for an individual, or a clinical outcome.

23. Related Research Product

24. Related Plan

25. Scientific References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216. https://doi.org/10.1056/NEJMoa2206038.
2. Sattar N, Linetzky B, Ruotolo G, et al. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. Journal of the American College of Cardiology. Published online June 3, 2026. https://doi.org/10.1016/j.jacc.2026.04.044.
3. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine. 2025;393:2409–2420. https://doi.org/10.1056/NEJMoa2505928.
4. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 2025;392:958–971. https://doi.org/10.1056/NEJMoa2410819.
5. Karagiannis T, et al. Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2023. https://doi.org/10.1111/dom.15272.
6. Correspondence. Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. New England Journal of Medicine. 2026;394:1550–1553. https://doi.org/10.1056/NEJMc2600572.
7. US Food and Drug Administration. MOUNJARO (tirzepatide) Prescribing Information. FDA prescribing information.
8. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021;398:1811–1824. https://doi.org/10.1016/S0140-6736(21)02188-7.
9. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine. 2022. Full text at PubMed Central.

26. Conclusion

Body weight is an important outcome in tirzepatide research, but it is not a complete representation of cardiometabolic health. HbA1c, blood pressure, lipid levels, waist circumference, kidney-related measurements, and selected biomarkers each provide different information about risk and treatment response.

The 2026 SURMOUNT-1 biomarker analysis adds useful evidence that tirzepatide treatment is associated with changes in several pathways related to inflammation, insulin resistance, adiposity, hepatic stress, endothelial dysfunction, and hemostasis. The findings are scientifically informative, but they do not establish that all changes are independent of weight reduction or that each change directly produces fewer cardiovascular events.

SURPASS-CVOT provides a different and essential type of evidence. In adults with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events, while superiority was not established. That conclusion should remain distinct from the results of biomarker studies.

The strongest interpretation is therefore neither that weight loss tells the whole story nor that every favorable biomarker proves cardiovascular protection. Tirzepatide affects multiple cardiometabolic measurements, but their meaning depends on the marker, the population, the comparator, and the clinical outcome being considered.

For clinical decision-making, established risk factors remain central. Biomarkers can enrich the scientific picture, but they should complement—not replace—validated assessment, evidence-based risk management, and individualized medical care.